Capricor Therapeutics price target raised to $54 from $22 at Oppenheimer

Oppenheimer raised the firm’s price target on Capricor Therapeutics (CAPR) to $54 from $22 and keeps an Outperform rating on the shares following deramiocel’s broadly positive Phase 3 results and the company’s financing. The firm believes deramiocel’s clinical profile stands second to none relative to approved Duchenne muscular dystrophy therapeutics, and its projected 2031 sales of about $1.1B in the U.S. alone through partner NS Pharma may prove conservative.